Home › Research › Treatments
Limitations of Sacubitril/Valsartan in the Management of Heart Failure
Yandrapalli S, Aronow WS, Mondal P, Chabbott DR.. American journal of therapeutics, 2017-03-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Background The PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) trial was a double-blind trial that randomized 8442 patients with heart failure (HF) with reduced ejection fraction (HFrEF) to receive twice daily dosing of either 200 mg of LCZ696 or 10 mg of enalapril in addition to standard medical therapy for HF. Areas of uncertainty Limitations of this trial include (1) sacubitril has not been tested by itself in the treatment of HFrEF; (2) the maximum recommended dose of valsartan for the treatment of HFrEF was used in this trial, but the maximum recommended dose of enalapril for the treatment of HFrEF was not used; (3) a run-in phase was used in this trial to test the tolerability of LCZ696, and patients who had adverse effects in this period were excluded from randomization; (4) the percent of blacks enrolled in this trial was only 5%; (5) LCZ696 caused a 14% incidence of hypotension; (6) neprilysin inhibition might favor the development of Alzheimer dementia, which was not assessed in the PARADIGM-HF trial; (7) patients with severe symptomatic HF were underrepresented in this trial; (8) major exclusions from this trial included an acute coronary event in the last 3 months, severe pulmonary disease, hepatic impairment, and an estimated glomerular filtration rate Data sources Review of the PARADIGM-HF trial. Results At 27-month follow-up, the PARADIGM-HF trial showed that compared with enalapril, LCZ696 reduced the composite of cardiovascular death or hospitalization for HF 20% (absolute risk reduction 4.7%, P Conclusions The numerous limitations discussed under the areas of uncertainty should be considered when prescribing LCZ696 for the treatment of HFrEF.
What this study adds
Evidence grade: High
The record lists 8,442 participants. This paper discusses limitations of a heart failure trial, including that neprilysin inhibition might favor the development of Alzheimer dementia, which was not assessed in that trial. Reported effect size: 4.7%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Yandrapalli, S., Aronow, W. S., Mondal, P., & Chabbott, D. R. (2017). Limitations of Sacubitril/Valsartan in the Management of Heart Failure. American journal of therapeutics. https://doi.org/10.1097/mjt.0000000000000473
Vancouver
Yandrapalli S, Aronow WS, Mondal P, Chabbott DR. Limitations of Sacubitril/Valsartan in the Management of Heart Failure. American journal of therapeutics. 2017. doi:10.1097/mjt.0000000000000473. PMID: 27574931.
BibTeX
@article{yandrapalli2017-27574931,
author = {Yandrapalli, S. and Aronow, W. S. and Mondal, P. and Chabbott, D. R.},
title = {{Limitations of Sacubitril/Valsartan in the Management of Heart Failure}},
journal = {American journal of therapeutics},
year = {2017},
doi = {10.1097/mjt.0000000000000473},
pmid = {27574931},
url = {https://doi.org/10.1097/mjt.0000000000000473}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results At 27-month follow-up, the PARADIGM-HF trial showed that compared with enalapril, LCZ696 reduced the composite of cardiovascular death or hospitalization for HF 20% (absolute risk reduction 4.7%, P < 0.001).
Why it matters
This paper discusses limitations of a heart failure trial, including that neprilysin inhibition might favor the development of Alzheimer dementia, which was not assessed in that trial. It does not test or show any effect on Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants8,442
- Effect size4.7%
- Evidence strengthHigh
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 44 of the 96 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (American journal of therapeutics) |
| Journal's citation record | 1 / 4 | American Journal of Therapeutics: journal h-index 83 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 3 / 4 | 8,442 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 26 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.4 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 3 / 6 | Cited 3.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author David R. Chabbott holds only 3 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | New York Medical College: institution h-index 505 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27574931) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 44 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 44 of the 96 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
187 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.